Aiming to “bend the curve toward longer disease-free survival” with improved safety in non-muscle-invasive bladder cancer (NMIBC), Tyra Biosciences Inc. CEO Todd Harris said the company has settled on ...
Plowshare Therapies LLC has completed its current fundraising initiative and raised $6.7 million to advance PLOW-101, its ...
In a recent study, researchers from the University of Western Australia and collaborating institutions proposed the use of precision molecular targeting and delivery strategies based on CRISPR/dCas9 ...
Ciliatech SAS received U.S. FDA investigational device exemption (IDE) for a feasibility study of Intercil Uveal Spacer, its implant to treat glaucoma.
Moonwalk Biosciences Inc. was founded in 2023 with $57 million in seed and series A financing to use its human genetics, epigenomics and multiomics discovery platform to discover new gene targets.
Orikine Bio SL is advancing lead candidate ORK-1 toward an IND submission and first-in-human studies for inflammatory bowel ...
Aceso Therapeutics SAS is collaborating with Aptar Pharma (Aptargroup Inc.) to advance the development of ACT-101, its antisense oligonucleotide (ASO) candidate designed to target the underlying ...
Odyssey Therapeutics Inc. has identified new receptor-interacting serine/threonine-protein kinase 2 (RIPK2; RIP-2) inhibitors potentially useful for the treatment of cancer, chronic granulomatous ...
Tictwo Therapeutics Inc. has disclosed new non-receptor tyrosine-protein kinase TYK2 (JH2 domain) inhibitors potentially useful for the treatment of cancer, inflammation, autoimmune disease and ...
The Cleveland Clinic Foundation has patented new plasminogen activator inhibitor 1 (SEPINE1; PAI-1) inhibitors potentially useful for the treatment of Crohn's disease and ulcerative colitis.
Novartis AG is the latest big pharma to turn to Alteogen Inc. to convert biologic drugs into subcutaneous (SC) formulations. Under the terms announced after Korean market hours Sept. 2, Alteogen ...
Gan & Lee Pharmaceuticals Co. Ltd. has signed its largest ex-China licensing agreement for obesity candidate bofanglutide ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results